Innate Pharma (IPH.PA) stock price, revenue, and financials

Innate Pharma market cap is €362.4 m, and annual revenue was €70.45 m in FY 2020

€362.4 M

IPH.PA Mkt cap, 10-Nov-2021

€70.5 M

Innate Pharma Revenue FY, 2020
Innate Pharma Net income (FY, 2020)-64 M
Innate Pharma EBIT (FY, 2020)-62.1 M
Innate Pharma Cash, 31-Dec-2020136.8 M
Get notified regarding key financial metrics and revenue changes at Innate PharmaLearn more
Banner background

Innate Pharma Revenue Breakdown

Embed Graph

Innate Pharma revenue breakdown by business segment: 15.0% from Government financing for research expenditures and 85.0% from Revenue from collaboration and licensing agreements

Innate Pharma Income Statement

Annual

EURFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

44.0m94.0m85.8m70.5m

Revenue growth, %

113%

Sales and marketing expense

516.0k

R&D expense

67.0m69.6m58.6m

General and administrative expense

17.0m18.1m31.2m

Operating expense total

84.0m87.7m90.4m

EBIT

(40.0m)5.1m(27.1m)(62.1m)

EBIT margin, %

(91%)5%(32%)(88%)

Interest expense

10.5m8.4m

Interest income

2.5m6.0m

Pre tax profit

(48.0m)2.7m(20.8m)(64.0m)

Income tax expense

368.0k(333.0k)

Net Income

(48.4m)3.0m(20.8m)(64.0m)

Half Year

EURH1, 2018H1, 2019

Revenue

23.0m59.2m

R&D expense

32.3m36.6m

General and administrative expense

5.6m9.3m

Operating expense total

37.9m45.9m

EBIT

(14.9m)9.5m

EBIT margin, %

(65%)16%

Interest expense

4.7m1.9m

Interest income

4.2m5.7m

Pre tax profit

(15.5m)13.2m

Income tax expense

(333.0k)

Net Income

(15.1m)13.2m

Innate Pharma Balance Sheet

Annual

EURFY, 2017FY, 2018FY, 2019FY, 2020

Cash

99.4m152.3m202.9m136.8m

Accounts Receivable

2.5m10.6m

Current Assets

137.5m319.6m237.6m173.5m

PP&E

10.7m10.2m11.7m11.7m

Total Assets

255.0m451.2m401.4m307.4m

Accounts Payable

20.0m28.6m

Short-term debt

1.3m1.3m

Current Liabilities

73.9m196.7m121.8m45.5m

Long-term debt

4.5m3.2m

Non-Current Liabilities

95.2m87.2m62.1m106.0m

Total Debt

5.9m4.5m

Common Stock

2.9m3.2m

Additional Paid-in Capital

234.9m299.9m

Retained Earnings

(103.6m)(137.8m)(134.9m)

Total Equity

86.0m167.2m217.4m156.0m

Debt to Equity Ratio

0.1 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

3 x2.7 x1.8 x2 x

Quarterly

EURQ2, 2019

Cash

149.4m

Accounts Receivable

5.5m

Current Assets

216.7m

PP&E

11.4m

Total Assets

352.6m

Accounts Payable

23.1m

Short-term debt

1.7m

Current Liabilities

94.5m

Long-term debt

3.2m

Non-Current Liabilities

76.7m

Total Debt

5.0m

Common Stock

3.2m

Additional Paid-in Capital

301.6m

Retained Earnings

(134.9m)

Total Equity

181.3m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.9 x

Innate Pharma Cash Flow

Annual

EURFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(48.4m)3.0m(20.8m)(64.0m)

Depreciation and Amortization

4.4m7.4m16.5m56.8m

Cash From Operating Activities

(48.1m)(32.5m)34.9m(51.8m)

Purchases of PP&E

(3.0m)(873.0k)

Cash From Investing Activities

(29.5m)24.3m(62.1m)(13.4m)

Long-term Borrowings

(1.2m)(1.3m)

Cash From Financing Activities

915.0k61.2m77.8m(1.2m)

Net Change in Cash

(76.5m)52.9m

Interest Paid

113.0k102.0k

Quarterly

EURQ2, 2018Q2, 2019

Net Income

(15.1m)13.2m

Depreciation and Amortization

2.4m6.8m

Cash From Operating Activities

(33.9m)59.6m

Purchases of PP&E

(709.0k)(738.0k)

Cash From Investing Activities

14.8m(61.8m)

Long-term Borrowings

(630.0k)(729.0k)

Cash From Financing Activities

(685.0k)(772.0k)

Net Change in Cash

(19.9m)(2.9m)

Interest Paid

55.0k44.0k

Innate Pharma Ratios

EURFY, 2017

EV/EBIT

-10.3 x

EV/CFO

-8.6 x

Revenue/Employee

234.2k

Debt/Equity

0.1 x

Financial Leverage

3 x

Innate Pharma Operating Metrics

Q2, 2019

Phase I Trials Products

3

Phase II Trials Products

5

Pre-Clinical Phase Products

7

Innate Pharma Employee Rating

3.97 votes
Culture & Values
4.7
Work/Life Balance
5
Senior Management
4.7
Salary & Benefits
4.2
Career Opportunities
3.2
Source